poly ADP ribose polymerase (PARP) inhibitor olaparib neoadjuvant breast cancer

Interviews and expert commentary tagged “poly ADP ribose polymerase (PARP) inhibitor olaparib neoadjuvant breast cancer” — the latest oncology research and clinical practice from the Audio Journal of Oncology.

Christian Singer MD: Neoadjuvant Olaparib Combination Beats Standard of Care in Patients with Homologous Recombination Deficient BRCA 1/2-Positive Triple-Negative Breast Cancer
Audio Journal of Oncology

Christian Singer MD: Neoadjuvant Olaparib Combination Beats Standard of Care in Patients with Homologous Recombination Deficient BRCA 1/2-Positive Triple-Negative Breast Cancer

Homologous Repair Deficient Triple Negative Breast Cancer Positive for BRCA1/2 Mutations Better with Neoadjuvant Olaparib + Carboplatin

5 August 2025
10:32
← Browse all episodes